1. SWAG SSG Haematology and Lymphoma Meeting
Clinical Research Network
West of England
SWAG SSG Haematology and Lymphoma Meeting
Wednesday 2nd November 2016

2. Clinical Research Network & Cancer Services
West ofEngland
SWAG - Somerset Wiltsire Avon & Gloucestershire
South West Children’s Cancer & Leukaemia
Research Network

3. NIHR CRN – what does it do?
Infrastructure that allows high-quality clinical research to take place in the NHS
Help researchers to set up clinical studies quickly and effectively
Support the life-sciences industry to deliver their research programmes in the NHS
Provide health professionals with research training
Work with patients to ensure their needs are at the very centre of all research activity.

4. NIHR CRN High Level Objectives
Increase number of participants into NIHR CRN portfolio studies
Target 650,000 in England pa
Target 22,000 in West of England pa
Increase the number of studies that deliver to time and target
Objective 80%
Increase number of commercial studies delivered through network
Reduce NHS study set up times
Reduce time taken to recruit first participant

5. Local Clinical Research Networks
Translation of national objectives for clinical research
Oversight of research activity within the geography of CRN - West of England in terms of:
Portfolio
Balance, new studies, feasibility, set up, industry trials
Performance
Support, network wide solutions, targets
People
Patient involvement, staff skill mix & flexibility, training, resources

6. 30 Clinical Specialties Ageing Anaesthetics & pain Cancer
Cardiovascular
Children
Critical Care
Dementia & Neurodegenerative
Dermatology
Diabetes
ENT
Gastroenterology
Genetics
Haematology
Health Services
Hepatology
Infectious Diseases
Injuries & Emergencies
Mental Health
Metabolic & Endocrine
Musculoskeletal
Neurological
Opthalmology
Oral & Dental
Primary Care
Public Health
Renal
Reproductive Health
Respiratory
Stroke
Surgery

7. Including lymphoma

8. Local CRN sub specialty leads
NCRI Clinical Studies Groups
NIHR CRN cancer leadership

9. National Clinical Studies Groups PPI Psychosocial & Survivorship
Imaging Adv. panel
Breast Cancer
CSG
Brain Tumours
CSG
Lung Cancer
CSG
Palliative & Supportive
Care
Head & Neck
CSG
Biomarkers Adv. panel
Upper GI Cancer
CSG
Consumer Liaison Group
Sarcoma
CSG
PPI
Colorectal Cancer
CSG
Melanoma
CSG
Kidney Cancer
CSG
Primary
Care
Lymphoma
CSG
Bladder Cancer
CSG
Screening, Prevention & Early Diagnosis
Haematol.
CSG
Testis Cancer
CSG
Prostate Cancer
CSG
Gynae Cancer
CSG
Children’s Cancer & Leukaemia
Teenage &
Young Adult
CTRad (Radiotherapy)

10. Cancer sub specialty lead role
Communicate and collaborate with clinical colleagues across the network re the portfolio of studies in their sub specialty
Action plan in place to increase access to research
Mapping portfolio across the network
Shared portfolio of studies
Improve referral pathways for research
Encourage more referral for research
Consider economies of scale for rare disease studies
Network wide planning for EOIs
Support and encourage teams to meet study targets

11. NIHR CRN Objectives for cancer
Recruit 20% of cancer incidence
West of England 1,909
Recruit 7.5% of cancer incidence into interventional studies
716
Include challenging studies
Cancer surgery – 4 recruits per 100,000 population
Radiotherapy – 6 recruits per 100,000 population
Rare cancers (<6 per 100,000) – 12 recruits per 100,000 population
Children & young people – 3 per 100,000 population
Teenagers & young adults – record number of year olds approached and/or participating in research

13. % Recruitment of cancer incidence to interventional studies by Local Clinical Research Network

14. % Recruitment to haematological cancer studies by LCRN 2016-17 to date

17. SWAG study recruitment 2016-17 to date Lymphoma Haematological cancer

18. Haematology Project Title Project type Primary Clinical Studies Group
BRAG
Open studies
Black
Study not reported recruitment or study has not recruited
Red
% Recruitment is more than 30 behind % time elapsed, i.e. Difference < -30
Amber
% Recruitment is less than 30 behind % elapsed time but more than 0 behind % elapsed time, i.e. -30 < Difference < 0
Green
% Recruitment is equal to or greater than % elapsed time, i.e. Difference >= 0
Grey
Unable to calculate RAG due to record missing at least one data point
Haematology
Project Title
Project type
Primary Clinical Studies Group
Project design
Site parent organisation
Principal Investigator
BRAG rating
Project site date open to recruitment
Project site planned recruitment end date
Recruited (total)
Project site target participants
AML 19
Non-commercial portfolio
Haematological oncology
Interventional
Gloucestershire Hospitals NHS Foundation Trust
Rye, Dr Adam
25.02%
06/01/2016
04/06/2021 10 25
University Hospitals Bristol NHS Foundation Trust
Mehta, Dr Priyanka
9.30%
03/12/2015
01/01/2021 13 48
AML18
Non-commercial portfolio
Haematological oncology
Interventional
Gloucestershire Hospitals NHS Foundation Trust
Rye, Dr Adam
58.29%
21/09/2015
20/10/2020 8 10
Great Western Hospitals NHS Foundation Trust
Sternberg, Dr Alex
-20.34%
23/10/2015 3
University Hospitals Bristol NHS Foundation Trust
Mehta, Dr Priyanka
18.61%
10/02/2015
31/08/2019 18 32
CARDAMON
Non-commercial portfolio
Haematological oncology
Interventional
Royal United Hospitals Bath NHS Foundation Trust
Moore, Dr Sally
40.41%
18/05/2016
11/01/2021 3 6
ELASTIC (TAP)
Non-commercial portfolio
Haematological oncology
Interventional
Great Western Hospitals NHS Foundation Trust
Sternberg, Dr Alex
-71.70%
23/03/2015
30/09/2016 1 3
FIGARO
Non-commercial portfolio
Haematological oncology
Interventional
University Hospitals Bristol NHS Foundation Trust
Protheroe, Dr Rachel
-11.21%
02/05/2014
31/10/2017 6 10

19. Project Title
Project type
Primary Clinical Studies Group
Project design
Site parent organisation
Principal Investigator
BRAG rating
Project site date open to recruitment
Project site planned recruitment end date
Recruited (total)
Project site target participants
FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab
Non-commercial portfolio
Haematological oncology
Interventional
Gloucestershire Hospitals NHS Foundation Trust
Frewin, Dr Rebecca
21.11%
29/01/2016
31/08/2018 3 6
Great Western Hospitals NHS Foundation Trust
Blesing, Dr Norbert
-22.07%
06/07/2015
20/08/2018 1 5
North Bristol NHS Trust
Otton, Dr Sophie
127.92%
29/01/2015
15/10/2018 7 4
University Hospitals Bristol NHS Foundation Trust
Lowry, Lisa
-36.85%
12/02/2014
30/06/2018 16
LI-1
Non-commercial portfolio
Haematological oncology
Interventional
Gloucestershire Hospitals NHS Foundation Trust
Rye, Dr Adam
-57.55%
08/05/2013
07/11/2016 5 12
University Hospitals Bristol NHS Foundation Trust
Mehta, Dr Priyanka
-12.07%
23/03/2012
01/12/2018 17 30
MAJIC
Non-commercial portfolio
Haematological oncology
Interventional
Gloucestershire Hospitals NHS Foundation Trust
Frewin, Dr Rebecca
-50.57%
28/03/2013
15/08/2015 5

20. Project Title
Project type
Primary Clinical Studies Group
Project design
Site parent organisation
Principal Investigator
BRAG rating
Project site date open to recruitment
Project site planned recruitment end date
Recruited (total)
Project site target participants
MDSBio
Non-commercial portfolio
Haematological oncology
Observational
Gloucestershire Hospitals NHS Foundation Trust
Lush, Dr Richard
301.31%
23/07/2009
28/02/2017
127 32
Great Western Hospitals NHS Foundation Trust
Sternberg, Dr Alex %
14/02/2007
24/06/2021
291 15
North Bristol NHS Trust
Whiteway, Dr Alastair
1.56%
09/11/2008
117
120
Royal United Hospitals Bath NHS Foundation Trust
Wexler, Dr Sarah
92.13%
07/01/2013 92 50
University Hospitals Bristol NHS Foundation Trust
Mehta, Dr Priyanka
947.33%
25/07/2012
104 10
MUK8
Non-commercial portfolio
Haematological oncology
Interventional
University Hospitals Bristol NHS Foundation Trust
Bird, Dr Jenny
-22.01%
18/02/2016
01/06/2018 1 12
MyeChild 01
Non-commercial portfolio
Haematological oncology
Interventional,Observational
University Hospitals Bristol NHS Foundation Trust
Tunstall, Dr Oliver
-4.65%
22/07/2016
30/04/2022 30
OPTIMAL: Optimising Renal outcome in Myeloma renal failure
Non-commercial portfolio
Haematological oncology
Interventional
Great Western Hospitals NHS Foundation Trust
Anwer, Dr Saiyed
-20.19%
22/10/2015
01/07/2017 2 5
Prospective Study of Second Line Therapy for Acute GVHD (POSTAGE)
Non-commercial portfolio
Haematological oncology
Observational
University Hospitals Bristol NHS Foundation Trust
Griffin, Dr James
15.36%
09/02/2015
01/10/2018 5 8

21. Project Title
Project type
Primary Clinical Studies Group
Project design
Site parent organisation
Principal Investigator
BRAG rating
Project site date open to recruitment
Project site planned recruitment end date
Recruited (total)
Project site target participants
Red cell transfusion and QoL in myelodysplastic syndromes (REDDS)
Non-commercial portfolio
Haematological oncology
Interventional
Great Western Hospitals NHS Foundation Trust
Sternberg, Dr Alex
-57.72%
26/01/2015
30/12/2016 1 3
RIAltO
Non-commercial portfolio
Haematological oncology
Interventional
Great Western Hospitals NHS Foundation Trust
Blesing, Dr Norbert
57.40%
18/12/2012
31/03/2016 7 4
Royal United Hospitals Bath NHS Foundation Trust
Knechtli, Dr Christopher
259.70%
20/02/2012
30/04/2017 2
Weston Area Health NHS Trust
Gamare, Rajesh
22.40%
03/10/2012
31/12/2017
TREATT: Trial to EvaluAte Tranexamic acid therapy in Thrombocytopenia
Non-commercial portfolio
Haematological oncology
Interventional
University Hospitals Bristol NHS Foundation Trust
Mumford, Dr Andrew
-5.34%
18/02/2016
30/08/2019 5 35
UK Haplo
Non-commercial portfolio
Haematological oncology
Interventional
University Hospitals Bristol NHS Foundation Trust
Protheroe, Dr Rachel
52.75%
26/06/2013
31/12/2018 17 15
UKALL 14
Non-commercial portfolio
Haematological oncology
Interventional
Gloucestershire Hospitals NHS Foundation Trust
Rye, Dr Adam
303.39%
28/11/2011
30/12/2016 8 2
Royal United Hospitals Bath NHS Foundation Trust
Knechtli, Dr Christopher
63.12%
21/06/2011 5
University Hospitals Bristol NHS Foundation Trust
Marks, Prof David
67.04%
04/02/2011
01/01/2018 30 20

22. Haematology continued
Project Title
Project type
Primary Clinical Studies Group
Project design
Site parent organisation
Principal Investigator
BRAG rating
Project site date open to recruitment
Project site planned recruitment end date
Recruited (total)
Project site target participants
UKALL60+
Non-commercial portfolio
Haematological oncology
Interventional
Great Western Hospitals NHS Foundation Trust
Blesing, Dr Norbert %
27/09/2013
28/02/2015 1
WT1 TCR-001
Non-commercial portfolio
Haematological oncology
Interventional
University Hospitals Bristol NHS Foundation Trust
Robinson, Dr Stephen
-29.74%
27/05/2015
01/01/2018 1 4
WT1TCR Phase I/II study of genemodified WT1 TCR therapy in MDS & AML patient
Non-commercial portfolio
Haematological oncology
Interventional
University Hospitals Bristol NHS Foundation Trust
Protheroe, Dr Rachel
36.21%
23/06/2016
31/12/2018 1 2

23. Lymphoma recruitment to time and target
Project Title
Project type
Primary Clinical Studies Group
Project design
Site parent organisation
Principal Investigator
BRAG rating
Project site date open to recruitment
Project site planned recruitment end date
Recruited (total)
Project site target participants
CHEMO-T
Non-commercial portfolio
Lymphoma
Interventional
Gloucestershire Hospitals NHS Foundation Trust
Benstead, Dr Kim
-56.99%
02/01/2014
31/03/2017 3 10
INCA
Non-commercial portfolio
Lymphoma
Interventional
Royal United Hospitals Bath NHS Foundation Trust
Knechtli, Dr Christopher
-50.29%
26/03/2015
01/07/2017 1 5
University Hospitals Bristol NHS Foundation Trust
Lowry, Lisa
-39.92%
02/09/2015
13/06/2017 4
MCL Biobank Observational Study
Non-commercial portfolio
Lymphoma
Observational
Gloucestershire Hospitals NHS Foundation Trust
Lush, Dr Richard
15.70%
20/04/2015
30/09/2019 5 10
North Bristol NHS Trust
Siddiq, Samreen
29.15%
21/01/2016 1 2
Royal United Hospitals Bath NHS Foundation Trust
Wexler, Dr Sarah
19.03%
03/05/2016 3 9
University Hospitals Bristol NHS Foundation Trust
Lowry, Lisa
-45.70%
26/02/2015
31/10/2017 30
Molecular profiling for lymphoma (MaPLE)
Non-commercial portfolio
Lymphoma
Observational
Great Western Hospitals NHS Foundation Trust
Blesing, Dr Norbert
-21.06%
03/12/2014
02/06/2016 53 50
Royal United Hospitals Bath NHS Foundation Trust
Knechtli, Dr Christopher
154.19%
04/12/2014
31/08/2018 41 20

24. Lymphoma continued
Project Title
Project type
Primary Clinical Studies Group
Project design
Site parent organisation
Principal Investigator
BRAG rating
Project site date open to recruitment
Project site planned recruitment end date
Recruited (total)
Project site target participants
Non-Hodgkin Lymphoma in Young Adults
Non-commercial portfolio
Lymphoma
Observational
University Hospitals Bristol NHS Foundation Trust
Lowry, Lisa
849.36%
17/12/2015
01/09/2017 9 1
PROCLIPI
Non-commercial portfolio
Lymphoma
Observational
Gloucestershire Hospitals NHS Foundation Trust
Benstead, Dr Kim
-8.65%
10/12/2015
01/06/2020 1 9
University Hospitals Bristol NHS Foundation Trust
Dunnill, Dr MGS
-16.94%
22/12/2015
31/12/2020 25
ProT4 (Prophylactic Transfer of CD4 Lymphocytes)
Non-commercial portfolio
Lymphoma
Interventional
University Hospitals Bristol NHS Foundation Trust
Robinson, Dr Stephen
350.68%
26/10/2012
07/11/2016 18 4
NCRN 3245 – Betalutin radioimmunotherapy for treatment of relapsed CD37+NHL . Commercial
Target 7. Recruited 6. Open at UHB. Currently suspended.

25. Recruitment to time and target for Taunton and Yeovil
Trial Name
Specialty
Commercial Study
Trust
Investigator Name
End Date of Recruitment Phase
Participant Recruitment Target
Recruitment (EDGE)
RAG
AML 19
Haematological oncology No
Taunton
Bolam, Dr Simon
01/01/2021 5 3 46
AML18
Mannari, Dr Deepak
20/10/2020 8 14
EBV associated NK/T cell malignancies
17/01/2017 2
-97
FLAIR: Front-Line therapy in CLL: Assessment of Ibrutinib + Rituximab
Austen, Dr Belinda
20/08/2018 59
GALACTIC
30/08/2018 6
-21
LI-1
Yeovil
07/11/2016 52
UKALL 14
29/12/2016 4 9
129
CHEMO-T
Lymphoma
31/03/2019 1
-38
31/03/2017 12
LEGEND
01/02/2018
-54
MCL Biobank Observational Study
31/10/2017
-23
-24
CANC Study of CT-P10 in patients with Low Tumour Burden Follicular Lymphoma
Yes
28/02/2018
-22

26. Studies in set up - Haematology
Studies in set up - Lymphoma

27. Useful links https://www.crn.nihr.ac.uk/
National and local network information including training programmes templates, tools, contacts, videos etc
Open data platform. Look at performance across whole CRN including all specialty areas
/csg.ncri.org.uk/portfolio/portfolio-maps/
View current national portfolio of open, closed and ‘in set up’ cancer studies
See where a study is open across the country
Search for a study to fit criteria. Good for horizon scanning, eligibility criteria

28. Contacts Research Delivery Manager – maxine.taylor@nihr.ac.uk
Cancer portfolio facilitator –